Brief: Neuren Pharmaceuticals Reassessing Capital Management Options
27/05/2026 11:33
BRIEF-Neuren Pharmaceuticals Reassessing Capital Management Options May 27 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX:
CURRENTLY REASSESSING CAPITAL MANAGEMENT OPTIONS INCLUDING CONTINUED BUYBACK PROGRAM AND COMMENCING FRANKED DIVIDENDS
TO CONFIRM OUTCOME OF ASSESSMENT IN AUGUST, DECIDED TO PAUSE BUYBACK
Further company coverage: NEU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neuren Pharmaceuticals
See all newsStrong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union
Australia's Neuren jumps as EU committee backs key drug authorisation
Brief: Neuren Pharmaceuticals Reassessing Capital Management Options
Brief: Neuren Pharmaceuticals Says Daybue Stix Now Broadly Available In US For Rett Syndrome